Details

Autor(en) / Beteiligte

• Martino, Massimo
• Pitino, Annalisa
• Gori, Mercedes
• Bruno, Benedetto
• Crescimanno, Alessandra
• Federico, Vincenzo
• Picardi, Alessandra
• Tringali, Stefania
• Ingrosso, Claudia
• Carluccio, Paola
• Pastore, Domenico
• Musuraca, Gerardo
• Paviglianiti, Annalisa
• Vacca, Adriana
• Serio, Bianca
• Storti, Gabriella
• Mordini, Nicola
• Leotta, Salvatore
• Cimminiello, Michele
• Prezioso, Lucia
• Loteta, Barbara
• Ferreri, Anna
• Colasante, Fabrizia
• Merla, Emanuela
• Giaccone, Luisa
• Busca, Alessandro
• Musso, Maurizio
• Scalone, Renato
• Di Renzo, Nicola
• Marotta, Serena
• Mazza, Patrizio
• Musto, Pellegrino
• Attolico, Immacolata
• Selleri, Carmine
• Canale, Filippo Antonio
• Pugliese, Marta
• Tripepi, Giovanni
• Porto, Gaetana
• Martinelli, Giovanni
• Carella, Angelo Michele
• Cerchione, Claudio

Titel

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

Ist Teil von

• Frontiers in oncology, 2021-09, Vol.11, p.740079-740079

Ort / Verlag

Frontiers Media S.A

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Despite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed to evaluate the reproducibility of the safety and efficacy of commercially available letermovir for CMV prophylaxis in a real-world setting. Endpoints were rates of clinically significant CMV infection (CSCI), defined as CMV disease or CMV viremia reactivation within day +100-+168. 204 adult CMV-seropositive allo-SCT recipients from 17 Italian centres (median age 52 years) were treated with LET 240 mg/day between day 0 and day +28. Overall, 28.9% of patients underwent a haploidentical, 32.4% a matched related, and 27.5% a matched unrelated donor (MUD) transplant. 65.7% were considered at high risk of CSCI and 65.2% had a CMV seropositive donor. Low to mild severe adverse events were observed in 40.7% of patients during treatment [gastrointestinal toxicity (36.3%) and skin rash (10.3%)]. Cumulative incidence of CSCI at day +100 and day +168 was 5.4% and 18.1%, respectively, whereas the Kaplan-Meier event rate was 5.8% (95% CI: 2.4-9.1) and 23.3% (95% CI: 16.3-29.7), respectively. Overall mortality was 6.4% at day +100 and 7.3% at day +168. This real-world experience confirms the efficacy and safety of CMV.